Search results for "embolism"

showing 10 items of 457 documents

Ultrasonography of the Lung.

2019

 High diagnostic accuracy, increasing clinical experience and technical improvements are good reasons to consider lung ultrasound (US) for the assessment of pleural and pulmonary diseases. In the emergency room and in intensive care, it is well acknowledged, but application in other settings is rare. The aim of this review is to update potential users in general radiology about the diagnostic scope of lung US and to encourage more frequent use of this generally underestimated lung imaging modality. Literature review was done independently by the two authors in MEDLINE (via PubMed) covering a time span from 2002 until 2017 using free text and Medical Subject Headings/MeSH. Article selection …

Lung Diseasesmedicine.medical_specialtyPleural effusionPoint-of-care testingAtelectasis030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineIntensive caremedicineHumansRadiology Nuclear Medicine and imagingIntensive care medicineThoracic WallLungUltrasonographybusiness.industryPleural Diseasesmedicine.diseasePulmonary embolismPneumonia030228 respiratory systemPneumothoraxPleurisyPoint-of-Care TestingAcute DiseaseChronic DiseasebusinessPulmonary EmbolismRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct

Ein Auswerteprogramm zur quantitativen Analyse von Messungen des alveolären Sauerstoffpartialdrucks (pAO2) mit der sauerstoffsensitiven 3He-MR-Tomogr…

2004

Purpose: To develop a software tool for quantitative analysis of alveolar oxygen partial pressure (p A O 2 ) as well as its time course during apnea. Material and Methods: T 1 -relaxation times of hyperpolarized 3 He are reduced by paramagnetic oxygen rendering 3 He-MRI sensitive to oxygen and thus allowing the assessment of the local oxygen partial pressure in the pulmonary airspaces. Oxygen-related relaxation and loss of polarization by RF-excitation can be discriminated by acquiring two image series with varying interscan delay and/or flip angles. Software was developed to calculate the p A O 2 and the decay rate in user-defined regions of interest (ROIs) automatically. Moreover, paramet…

LungMaterials sciencemedicine.diagnostic_testbusiness.industrychemistry.chemical_elementMagnetic resonance imagingPartial pressuremedicine.diseaseVentilation/perfusion ratioOxygenPulmonary embolismSoftwareNuclear magnetic resonancemedicine.anatomical_structurechemistrymedicineRadiology Nuclear Medicine and imagingRespiratory systembusiness
researchProduct

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

2013

BackgroundWhether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. MethodsIn a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically re…

MESH: Pulmonary EmbolismMale[SDV]Life Sciences [q-bio]Kaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawMESH: Double-Blind Method030212 general & internal medicineMESH: WarfarinMESH: AgedMESH: Middle AgedHazard ratioGeneral MedicineVenous ThromboembolismMiddle AgedThrombosis3. Good healthPulmonary embolismAnesthesiaFemaleAnticoagulants EdoxabanMESH: HemorrhageAndexanet alfamedicine.drugMESH: EnoxaparinHemorrhageMESH: AnticoagulantsMESH: Drug Administration ScheduleDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodAged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; WarfarinmedicineHumansEnoxaparinAdverse effectMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryWarfarinAnticoagulantsmedicine.diseaseMESH: MalechemistryWarfarinbusinessPulmonary EmbolismMESH: FemaleNew England Journal of Medicine
researchProduct

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

2021

Summary Objective To determine the incidence, characteristics, and risk factors of pulmonary embolism (PE) among patients hospitalized for COVID-19. Patients and Methods We performed a prospective observational study of a randomly selected cohort of consecutive patients hospitalized for COVID-19 infection between March 8, 2020 through April 25, 2020. All eligible patients underwent a computed tomography pulmonary angiography independently of their PE clinical suspicion and were pre-screened for a baseline elevated D-dimer level. Results 119 patients were randomly selected from the 372 admitted to one tertiary hospital in Valencia (Spain) for COVID-19 infection during the period of study. Se…

Male0301 basic medicineCTPA Computed tomography pulmonary angiographyAUC-ROC Area under curve ROCPCR polymerase chain reaction0302 clinical medicineRisk FactorsspO2 Oxygen saturationIL6 Interleukin-6Pulmonary angiographySD Standard deviationMedicineProspective Studies030212 general & internal medicineProspective cohort studyComputed tomographyFramingham Risk ScoreIncidenceIncidence (epidemiology)RV Right ventricleHazard ratioVenous ThromboembolismMiddle AgedAo Aortic arteryPulmonary embolismCXR chest X-rayHospitalizationInfectious DiseasesCohortCRP C-reactive proteinFemalePA Pulmonary artery trunkMicrobiology (medical)medicine.medical_specialty030106 microbiologysPESI Simplified Pulmonary Embolism Severity IndexBMI Body mass indexPE Pulmonary embolismLV Left ventricleVTE Venous thromboembolismFibrin Fibrinogen Degradation Products03 medical and health sciencesInternal medicineHumansICU Intensive care unitsACE2 Angiotensin converting enzyme-2AgedInflammationLDH Lactate dehydrogenaseSARS-CoV-2 Severe acute respiratory syndrome coronavirus 2CI Confidence intervalbusiness.industryPulmonary embolismCOVID-19AnticoagulantsThrombosisRR Respiratory ratemedicine.diseaseConfidence intervalCHOD CRP concentration + Heart rate + Oxygen saturation + D-dimer levelsSpainHR Hazard RatioCommentarybusinessJournal of Infection
researchProduct

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants

2020

AbstractAs a result of the successful completion of their respective phase III studies compared with vitamin K antagonists (VKAs), four direct oral anticoagulants (DOACs) have been approved for the treatment and secondary prevention of venous thromboembolism (VTE). These DOACs—apixaban, dabigatran, edoxaban, and rivaroxaban—have subsequently seen a steady uptake among clinicians since their approval. Despite the suitability of DOACs for a broad range of patients, they are not appropriate in certain situations, whereas in others they require additional considerations such as dose reductions. Subanalyses of phase III trials and studies on specific VTE patient populations have been conducted t…

Male0301 basic medicineComorbidity030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicinePregnancyEdoxabanNeoplasmsSecondary PreventionChildspecial populationsAge FactorsVenous ThromboembolismHematologyMiddle AgedTreatment OutcomePractice Guidelines as TopicFemaleKidney Diseasesmedicine.drugAdultmedicine.medical_specialtyMEDLINEHemorrhagecomorbiditiesdirect oral anticoagulantsDabigatran03 medical and health sciencesmedicineHumansLactationDosingIntensive care medicineAgedDose-Response Relationship Drugbusiness.industryPatient SelectionPregnancy Complications HematologicContraindications DrugAnticoagulantsmedicine.diseaseComorbidityReview articleClinical trial030104 developmental biologyClinical Trials Phase III as TopicchemistrybusinessVenous thromboembolismFactor Xa InhibitorsThrombosis and Haemostasis
researchProduct

Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population‐Based Gutenberg Health Study

2018

Background Preclinical data have indicated a link between use of vitamin K antagonists ( VKA ) and detrimental effects on vascular structure and function. The objective of the present study was to determine the relationship between VKA intake and different phenotypes of subclinical cardiovascular disease in the population. Methods and Results Clinical and laboratory data, as well as medical–technical examinations were assessed from 15 010 individuals aged 35 to 74 years during a highly standardized 5‐hour visit at the study center of the population‐based Gutenberg Health Study. In total, the study sample comprised 287 VKA users and 14 564 VKA nonusers. Multivariable analysis revealed an in…

Male0301 basic medicineEpidemiologyPROGRESSION030204 cardiovascular system & hematologyVitamin kCarotid Intima-Media ThicknessTHERAPYGastroenterologyAdrenomedullin0302 clinical medicineRisk Factorscardiovascular diseaseGermanyAtrial FibrillationNatriuretic Peptide BrainMatrix gla proteinOriginal ResearchVenous Thrombosisoral anticoagulationRISKbiologyMiddle AgedStrokevitamin K antagonistsC-Reactive ProteinCardiovascular DiseasesFemaleCardiology and Cardiovascular MedicineAtrial Natriuretic Factormedicine.drugAdultmedicine.medical_specialtyPopulation basedMATRIX GLA-PROTEINWARFARIN03 medical and health sciencesVascular StiffnessInternal medicineORAL ANTICOAGULANTmedicineHumansAnkle Brachial IndexVascular structureProtein PrecursorsAgedInflammationVascular diseasebusiness.industryWarfarinAnticoagulantsFibrinogenStroke Volumepharmacogenomic variantsARTERIALmedicine.diseasePreclinical dataPeptide FragmentsCALCIFICATION030104 developmental biologyAsymptomatic DiseasesPhenprocoumonbiology.proteinPulmonary EmbolismbusinessCalcificationJournal of the American Heart Association
researchProduct

Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension

2019

Background Inflammation and incomplete thrombus resolution leading to obstructive fibrotic remodelling are considered critical mechanisms for the development of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE). Osteopontin (OPN) is involved in a variety of biological processes including inflammation and tissue fibrosis. Methods OPN plasma concentrations were measured in 70 CTEPH and 119 PE patients. Tissue material from 6 CTEPH patients removed during pulmonary endarterectomy and murine venous thrombi induced by subtotal ligation of the inferior vena cava in C57BL/6 mice were analysed by (immuno)histochemistry. Results CTEPH patients had higher OPN plasma…

Male0301 basic medicinePathologymedicine.medical_specialtyHypertension Pulmonarymedicine.medical_treatmentInflammationEndarterectomy030204 cardiovascular system & hematologyInferior vena cavaTranslational Research BiomedicalPathogenesisMice03 medical and health sciences0302 clinical medicinestomatognathic systemFibrosisThromboembolismmedicineAnimalsHumansProspective StudiesOsteopontinThrombusMyofibroblastsAgedEndarterectomyInflammationbiologybusiness.industryThrombosisHematologyMiddle AgedPrognosismedicine.diseaseFibrosisPulmonary embolismMice Inbred C57BL030104 developmental biologymedicine.veinChronic Diseasebiology.proteinFemaleOsteopontinmedicine.symptomPulmonary EmbolismbusinessBiomarkersThrombosis and Haemostasis
researchProduct

Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observa…

2020

Background: The pathogenesis of arterial and venous thrombosis is in large part interlaced. How much platelet phenotype relates to acute venous thromboembolism (VTE) independent of the underlying cardiovascular profile is presently poorly investigated.Methods: Platelet count and mean platelet volume (MPV), platelet aggregation in whole blood and platelet rich plasma (PRP), platelet-dependent thrombin generation (TG) and platelet surface activation markers were measured under standardized conditions. Machine learning was applied to identify the most relevant characteristics associated with VTE from a large array (N = 58) of clinical and plateletrelated variables.Findings: VTE cases (N = 159)…

Male0301 basic medicinePlatelet Aggregationlcsh:MedicineDETERMINANTSGastroenterologyMachine LearningPathogenesisACTIVATION0302 clinical medicineRisk FactorsPlateletWhole bloodlcsh:R5-920AspirinOUTCOMESThrombinVenous ThromboembolismGeneral MedicineMiddle AgedThrombosisVenous thrombosis030220 oncology & carcinogenesisAcute DiseaseFemaleDisease Susceptibilitylcsh:Medicine (General)Research Papermedicine.drugBlood Plateletsmedicine.medical_specialtyPlatelet Function TestsGeneral Biochemistry Genetics and Molecular BiologyImmunophenotyping03 medical and health sciencesACUTE PULMONARY-EMBOLISMRISK-FACTORInternal medicinemedicineHumansMean platelet volumeMETAANALYSISAgedPlatelet Countbusiness.industrylcsh:RPlatelet Activationmedicine.diseasePREVENTIONASPIRINTHROMBOSIS030104 developmental biologyPlatelet-rich plasmaVOLUMEbusinessBiomarkersEBioMedicine
researchProduct

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism…

2021

Male2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Unfractionated heparinLetter to the Editors-in-ChiefCohort StudiesFibrin Fibrinogen Degradation ProductsInternal medicineD-dimerHumansMedicineIn patientHeparinbusiness.industryPulmonary embolismCOVID-19HematologyHeparinmedicine.diseaseCOVID-19 Drug TreatmentPulmonary embolismRadiological weaponD-dimerbusinessCohort studymedicine.drug
researchProduct

Non-vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis

2019

Oral anticoagulants (OACs) are widely used for prevention of systemic thromboembolism, including the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy (DAPT). A typical example is a patient with AF and stable coronary artery disease or acute coronary syndrome (ACS), treated by percutaneous coronary intervention. In recent years, with the introduction of NOACs, triple or dual therapy has become safer. Regardless of these indications for the use of NOACs, rivaroxaban at a reduced dose has proved to efficiently reduce the risk o…

MaleAcute coronary syndromemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentCardiologyAdministration OralCoronary Artery Disease030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineRivaroxabanThromboembolismInternal medicinemedicineHumansMyocardial infarctionStrokeSocieties MedicalRivaroxabanAspirinAspirinbusiness.industryAnticoagulantsPercutaneous coronary interventionVitamin K antagonistAtherosclerosismedicine.diseaseCardiologyDrug Therapy CombinationFemalePolandCardiology and Cardiovascular Medicinebusinessmedicine.drugKardiologia Polska
researchProduct